Oxaliplatin Accord

Oxaliplatin, the active ingredient in Oxaliplatin Accord, is a platinum‑based chemotherapy presented as a generic strength for intravenous use. It treats colorectal cancer and other solid tumours in adult patients. GNH USA supplies Oxaliplatin Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

GNH USA supplies Oxaliplatin Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Oxaliplatin Accord is a platinum‑based chemotherapy used in the treatment of cancers that involve the gastrointestinal tract and related pathways.

- Colorectal cancer: improves survival rates when combined with fluorouracil and leucovorin. - Gastric cancer: used as part of combination regimens for advanced disease. - Pancreatic cancer: contributes to tumor response in multi‑drug protocols. - Ovarian cancer: employed in certain platinum‑sensitive relapse settings. - Esophageal cancer: added to chemotherapeutic schedules for locally advanced cases.

Oxaliplatin Accord may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: mild to moderate gastrointestinal upset. - Peripheral neuropathy: tingling or numbness, often dose‑related. - Diarrhoea: loose stools that may require supportive care. - Fatigue: general tiredness affecting daily activities. - Thrombocytopenia: reduced platelet count increasing bleeding risk.

Serious or Rare Side Effects: - Severe hypersensitivity reactions: anaphylaxis or bronchospasm. - Acute neurotoxicity: sudden onset of muscle cramps or spasms. - Hematologic toxicity: neutropenia or severe anemia. - Cardiotoxicity: rare arrhythmias or myocardial injury. - Renal impairment: acute kidney injury in susceptible patients.

When handling Oxaliplatin Accord, clinicians should observe specific safety measures and patient monitoring protocols.

- Renal function assessment: evaluate baseline creatinine and adjust if impaired. - Hepatic function monitoring: check liver enzymes before and during therapy. - Neuropathy surveillance: assess for sensory changes at each visit. - Hematologic monitoring: perform regular CBCs to detect cytopenias. - Pregnancy and lactation warning: avoid use unless benefits outweigh risks. - Store at ambient temperature: keep in original container, protect from light and moisture.

Oxaliplatin may interact with several concomitant medications, requiring careful review.

Major Interactions (Avoid): - Nephrotoxic agents: concurrent use with aminoglycosides may increase kidney injury risk. - Myelosuppressive chemotherapy: combined regimens can amplify bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Anticoagulants: may heighten bleeding tendency due to thrombocytopenia.\n- Antiemetic agents: some may alter oxaliplatin pharmacokinetics. - NSAIDs: can affect platelet function and increase gastrointestinal toxicity. - Vitamin C high‑dose supplements: may reduce platinum‑drug efficacy. - CYP 3‑ ?